Cut through the hype of Multi-Cancer Early Detection (MCED) tests and learn how to counsel patients on the real-world utility, false-positive risks, and the "stage shift" debate of these emerging blood assays. We are joined by world-renowned oncologist Dr. Margaret Tempero,UCSF Cancer Early Detection and Interception, to discuss whether these tests are truly ready for clinical prime time.

Show Segments

00:00 Introduction
01:57 Current Cancer Screening Programs
06:05 Emerging Blood-Based Cancer Tests
11:55 Test Characteristics and Limitations
18:05 Practical Considerations for Patients
25:33 Direct-to-Consumer Testing/Whole Body MRIs
36:46 Navigating Positive Test Results
45:10 Anxiety and Patient Education
47:08 Future Directions in Cancer Screening
Outro

Credits

Producer, Writer, Show Notes, Infographic, Cover Art: Molly Heublein MD
Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP
Reviewer: Sai S Achi MD,MBA,FACP
Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP
Technical Production: PodPaste
Guest: Margaret Tempero, MD

Disclosures

Dr. Tempero reports the following financial relationships:
Grail (research support), Global Bio Access Fund (Advisor), Bristol Myers Squibb (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Astra Zeneca (Membership on Advisory Committees or Review Panels, Board Membership, etc), Immunovia (Membership on Advisory Committees or Review Panels, Board Membership, etc.), Merck (advisory committee), Renovo Rx (advisory committee), Urogen (Advisor). Financial relationships have not ended.
The Curbsiders report no relevant financial disclosures.

Sponsor: FIGS

Curbsiders listeners can get 15% off. Just go to WearFIGS.com and use code FIGSRX.

Sponsor: Freed

Try Freed Front Desk free for 7 days at getfreed.ai/front-desk.

Sponsor: Quince

Go to Quince.com/curb for free shipping on your order and 365-day returns. Now available in Canada, too.